LFA-1-deficient mice show normal CTL responses to virus but fail to reject immunogenic tumor

R Schmits1, T M Kündig, D M Baker

  • 1Amgen Institute, Ontario Cancer Institute, Department of Medical Biophysics, Toronto, Canada.

Insights

Mice lacking leukocyte function-associated antigen-1 (LFA-1) showed impaired peripheral immune responses, including tumor rejection. However, their ability to fight systemic viral infections remained normal, indicating a selective immune defect.

Area of Science:

  • Immunology
  • Cellular Biology
  • Molecular Medicine

Background:

  • Leukocyte function-associated antigen-1 (LFA-1), also known as CD11a/CD18, is crucial for lymphocyte recirculation and cell-to-cell interactions.
  • Integrins like LFA-1 mediate essential immune cell functions.

Purpose of the Study:

  • To investigate the specific role of CD11a in immune responses, particularly in the context of viral infections and tumor immunity.
  • To determine if CD11a deficiency impacts T cell responses to systemic infections versus peripheral immune challenges.

Main Methods:

  • Analysis of CD11a-deficient mice.
  • In vitro assays for homotypic aggregation and mitogen response.
  • Assessment of cytotoxic T cell (CTL) responses to viral infections (LCMV, VSV).
  • Evaluation of tumor rejection and immune priming against tumor-specific antigens in vivo.

Main Results:

  • CD11a-deficient leukocytes exhibited defects in homotypic aggregation, mixed lymphocyte reactions, and mitogen responses.
  • Mutant mice mounted effective CTL responses against systemic viral infections.
  • LFA-1-deficient mice failed to reject immunogenic tumors and showed impaired priming to tumor antigens.
  • CD11a deficiency resulted in a selective impairment of peripheral immune responses.

Conclusions:

  • CD11a is essential for certain peripheral immune responses, such as tumor immunity and immune priming.
  • The absence of CD11a does not compromise the ability to combat systemic viral infections, highlighting a selective role in adaptive immunity.

Related Concept Videos